You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Loncastuximab Tesirine

Showing 1 - 25 of 40
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Loncastuximab Tesirine
  • (no location specified)
Jul 24, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

B-cell Lymphoma, Burkitt Lymphoma Trial in Milwaukee (Etoposide, Doxorubicin, Cyclophosphamide)

Not yet recruiting
  • B-cell Lymphoma
  • Burkitt Lymphoma
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Jun 11, 2022

Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

Recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • Miami, Florida
    University of Miami
Jul 12, 2022

Follicular Lymphoma Trial in Miami (Loncastuximab tesirine, Rituximab)

Recruiting
  • Follicular Lymphoma
  • Miami, Florida
    University of Miami
Jul 11, 2022

Large B-cell Lymphoma, Lymphoma Trial in Houston (Loncastuximab Tesirine)

Not yet recruiting
  • Large B-cell Lymphoma
  • Lymphoma
  • Loncastuximab Tesirine
  • Houston, Texas
    MD Anderson Cancer Center
Jul 14, 2022

Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • loncastuximab tesirine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Jun 24, 2022

Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

Not yet recruiting
  • Post-Transplant Lymphoproliferative Disorder
  • +10 more
  • Loncastuximab Tesirine
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2022

Waldenstrom Macroglobulinemia Trial in Boston (Loncastuximab Tesirine, Dexamethasone)

Recruiting
  • Waldenstrom Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 1, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Cleveland (Loncastuximab tesirine, Venetoclax)

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
May 20, 2022

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

DLBCL Trial in Cleveland (Loncastuximab tesirine, Prednisone, Rituximab)

Withdrawn
  • Diffuse Large B-Cell Lymphoma
  • Loncastuximab tesirine
  • +5 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center
Mar 15, 2022

Diffuse Large B-cell Lymphoma Trial in United States (Loncastuximab Tesirine, Rituximab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Reno, Nevada
  • +4 more
Jul 1, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

Withdrawn
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023

B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Loncastuximab Tesirine
  • +4 more
  • Pembroke Pines, Florida
  • +19 more
Jul 22, 2022

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Worldwide (Loncastuximab Tesirine, Idelalisib)

Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Las Vegas, Nevada
  • +33 more
Jul 26, 2022

DLBCL Trial in Japan (MT-2111)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Nagoya-shi, Aichi, Japan
  • +3 more
Jan 12, 2023

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Italy (Consolidation with ADCT-402 (loncastuximab

Recruiting
  • Relapsed Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
  • Brescia, Italy
  • +19 more
Apr 22, 2022

DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spain, United States (Loncastuximab Tesirine and Durvalumab)

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Loncastuximab Tesirine and Durvalumab
  • Birmingham, Alabama
  • +13 more
Sep 28, 2021

DLBCL Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Worldwide (Loncastuximab tesirine)

Completed
Has Results
  • Diffuse Large B-Cell Lymphoma Refractory
  • Diffuse Large B-cell Lymphoma Recurrent
  • Loncastuximab tesirine
  • Duarte, California
  • +36 more
Aug 18, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Worldwide (Loncastuximab Tesirine, Rituximab, Gemcitabine)

Recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Loncastuximab Tesirine
  • +3 more
  • La Jolla, California
  • +59 more
Aug 4, 2022

Relapsed or Refractory DLBCL (R/R DLBCL) Trial (Loncastuximab Tesirine)

No longer available
  • Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
  • Loncastuximab Tesirine
  • (no location specified)
May 10, 2021

Acute Lymphoblastic Leukemia Trial in United States (ADCT-402)

Terminated
Has Results
  • Acute Lymphoblastic Leukemia
  • La Jolla, California
  • +9 more
Apr 27, 2021